Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Leukemia

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 60 articles: HTML format

Single Articles

June 2025
1. HUANG BJ, Meyer LK, Alonzo TA, Wang YC, et al
   Hematopoietic Stem Cell Transplantation Outcomes for High-Risk AML: A Report From the Children's Oncology Group.
   J Clin Oncol. 2025;43:1961-1971.
   PubMed     Abstract available
   
   
   
2. SHARMAN JP, Munir T, Grosicki S, Roeker LE, et al
   Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321).
   J Clin Oncol. 2025 Jun 6:JCO2500166. doi: 10.1200/JCO-25-00166.
   PubMed     Abstract available
   
   
   May 2025
3. SHADMAN M, Munir T, Ma S, Lasica M, et al
   Zanubrutinib and Venetoclax for Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results.
   J Clin Oncol. 2025 May 31:JCO2500758. doi: 10.1200/JCO-25-00758.
   PubMed     Abstract available
   
   
   April 2025
4. KIRKWOOD AA, Goulden N, Moppett J, Samarasinghe S, et al
   High-Dose Methotrexate in Children and Young Adults With ALL and Lymphoblastic Lymphoma: Results of the Randomized Phase III Study UKALL 2011.
   J Clin Oncol. 2025 Apr 7:JCO2401851. doi: 10.1200/JCO-24-01851.
   PubMed     Abstract available
   
   
   March 2025
5. DAVIDS MS, Ryan CE, Lampson BL, Ren Y, et al
   Erratum: Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naive Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
   J Clin Oncol. 2025 Mar 18:JCO2500466. doi: 10.1200/JCO-25-00466.
   PubMed    
   
   
   
6. TREGNAGO C, Benetton M, Ries RE, Peplinski JH, et al
   Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration.
   J Clin Oncol. 2025;43:972-984.
   PubMed     Abstract available
   
   
   February 2025
7. RUSSELL NH, Thomas A, Hills RK, Thomas I, et al
   Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.
   J Clin Oncol. 2025;43:694-704.
   PubMed     Abstract available
   
   
   
8. KATO M, Okamoto Y, Imamura T, Kada A, et al
   JCCG ALL-B12: Evaluation of Intensified Therapies With Vincristine/Dexamethasone Pulses and Asparaginase and Augmented High-Dose Methotrexate for Pediatric B-ALL.
   J Clin Oncol. 2025;43:567-577.
   PubMed     Abstract available
   
   
   
9. ROLOFF GW, Aldoss I, Kopmar NE, Lin C, et al
   Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
   J Clin Oncol. 2025;43:558-566.
   PubMed     Abstract available
   
   
   January 2025
10. GYURKOCZA B, Nath R, Seropian S, Choe H, et al
    Randomized Phase III SIERRA Trial of (131)I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
    J Clin Oncol. 2025;43:201-213.
    PubMed     Abstract available
    
    
    December 2024
11. KANTARJIAN H, Short NJ, Haddad FG, Jain N, et al
    Results of the Simultaneous Combination of Ponatinib and Blinatumomab in Philadelphia Chromosome-Positive ALL.
    J Clin Oncol. 2024;42:4246-4251.
    PubMed     Abstract available
    
    
    
12. ROY A, Brander DM, Hill EG, Halabi S, et al
    Statistical Perspectives and Meta-Analytic Approaches in Surrogate End Point Evaluation for Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2024 Dec 12:JCO2401881. doi: 10.1200/JCO-24-01881.
    PubMed    
    
    
    
13. SHADMAN M, Munir T, Robak T, Brown JR, et al
    Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.
    J Clin Oncol. 2024 Dec 8:JCO2402265. doi: 10.1200/JCO-24-02265.
    PubMed     Abstract available
    
    
    
14. DAVIDS MS, Ryan CE, Lampson BL, Ren Y, et al
    Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naive Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease.
    J Clin Oncol. 2024 Dec 7:JCO2402503. doi: 10.1200/JCO-24-02503.
    PubMed     Abstract available
    
    
    
15. VERSLUIS J, Metzner M, Wang A, Gradowska P, et al
    Risk Stratification in Older Intensively Treated Patients With AML.
    J Clin Oncol. 2024;42:4084-4094.
    PubMed     Abstract available
    
    
    November 2024
16. LANGERBEINS P, Robrecht S, Nieper P, Cramer P, et al
    Ibrutinib in Early-Stage Chronic Lymphocytic Leukemia: The Randomized, Placebo-Controlled, Double-Blind, Phase III CLL12 Trial.
    J Clin Oncol. 2024 Nov 27:JCO2400975. doi: 10.1200/JCO.24.00975.
    PubMed     Abstract available
    
    
    
17. HEIKAMP EB, Armstrong SA
    Revumenib Revises the Treatment Landscape for KMT2A-r Leukemia.
    J Clin Oncol. 2024 Nov 7:JCO2401265. doi: 10.1200/JCO-24-01265.
    PubMed    
    
    
    October 2024
18. CHEVALLIER P, Leguay T, Delord M, Salek C, et al
    Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22(+) Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2024 Oct 17:JCO2400490. doi: 10.1200/JCO.24.00490.
    PubMed     Abstract available
    
    
    September 2024
19. ROLLIG C, Steffen B, Schliemann C, Mikesch JH, et al
    Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.
    J Clin Oncol. 2024 Sep 16:JCO2400235. doi: 10.1200/JCO.24.00235.
    PubMed     Abstract available
    
    
    
20. KIM R, Chalandon Y, Rousselot P, Cayuela JM, et al
    Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study.
    J Clin Oncol. 2024;42:3140-3150.
    PubMed     Abstract available
    
    
    
21. VALLEJO BA, Ansari A, Parikh SA, Achenbach SJ, et al
    Risk of Incident Melanoma Among Individuals With Low-Count Monoclonal B-Cell Lymphocytosis.
    J Clin Oncol. 2024 Sep 4:JCO2400332. doi: 10.1200/JCO.24.00332.
    PubMed     Abstract available
    
    
    August 2024
22. SIMON F, Ligtvoet R, Robrecht S, Cramer P, et al
    Endpoint Surrogacy in First-Line Chronic Lymphocytic Leukemia.
    J Clin Oncol. 2024 Aug 30:JCO2401192. doi: 10.1200/JCO.24.01192.
    PubMed     Abstract available
    
    
    
23. CHANG TC, Chen W, Qu C, Cheng Z, et al
    Genomic Determinants of Outcome in Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2024 Aug 9:JCO2302238. doi: 10.1200/JCO.23.02238.
    PubMed     Abstract available
    
    
    
24. ISSA GC, Aldoss I, Thirman MJ, DiPersio J, et al
    Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
    J Clin Oncol. 2024 Aug 9:JCO2400826. doi: 10.1200/JCO.24.00826.
    PubMed     Abstract available
    
    
    
25. YOSHIMURA S, Li Z, Gocho Y, Yang W, et al
    Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia.
    J Clin Oncol. 2024 Aug 5:JCO2400500. doi: 10.1200/JCO.24.00500.
    PubMed     Abstract available
    
    
    
26. TURCOTTE LM, Neglia JP
    Duress and Distress Versus a Neurocognitive Mess: The Challenges of Procedural Sedation in Pediatric B-ALL.
    J Clin Oncol. 2024;42:2628-2631.
    PubMed     Abstract available
    
    
    
27. ALEXANDER S, Kairalla JA, Gupta S, Hibbitts E, et al
    Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study.
    J Clin Oncol. 2024;42:2671-2679.
    PubMed     Abstract available
    
    
    July 2024
28. MATAVA CT, Peyton J, von Ungern-Sternberg BS, Ing C, et al
    Propofol, Anesthesia, and Neurocognitive Outcomes in Patients With Pediatric Leukemia: Are We Missing the Forest for the Trees?
    J Clin Oncol. 2024 Jul 24:JCO2400856. doi: 10.1200/JCO.24.00856.
    PubMed    
    
    
    June 2024
29. TIERENS A, Arad-Cohen N, Cheuk D, De Moerloose B, et al
    Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease.
    J Clin Oncol. 2024;42:2174-2185.
    PubMed     Abstract available
    
    
    
30. TIONG IS, Hiwase DK, Abro E, Bajel A, et al
    Targeting Molecular Measurable Residual Disease and Low-Blast Relapse in AML With Venetoclax and Low-Dose Cytarabine: A Prospective Phase II Study (VALDAC).
    J Clin Oncol. 2024;42:2161-2173.
    PubMed     Abstract available
    
    
    
31. KITTAI AS, Bond D, Huang Y, Bhat SA, et al
    Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
    J Clin Oncol. 2024;42:2071-2079.
    PubMed     Abstract available
    
    
    
32. REED DR, Tulpule A, Metts J, Trucco M, et al
    Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials.
    J Clin Oncol. 2024 Jun 6:JCO2302717. doi: 10.1200/JCO.23.02717.
    PubMed     Abstract available
    
    
    May 2024
33. DAVER NG, Craddock C
    Moving Toward Total Therapy in AML: Personalized Treatments Improve Post-Transplant Outcome.
    J Clin Oncol. 2024;42:1731-1733.
    PubMed    
    
    
    
34. WANG ES, Goldberg AD, Tallman M, Walter RB, et al
    Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML.
    J Clin Oncol. 2024;42:1776-1787.
    PubMed     Abstract available
    
    
    
35. VAN DER SLUIS IM, Brigitha LJ, Fiocco M, de Groot-Kruseman HA, et al
    Continuous PEGasparaginase Dosing Reduces Hypersensitivity Reactions in Pediatric ALL: A Dutch Childhood Oncology Group ALL11 Randomized Trial.
    J Clin Oncol. 2024;42:1676-1686.
    PubMed     Abstract available
    
    
    
36. SHORT NJ, Daver N, Dinardo CD, Kadia T, et al
    Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML.
    J Clin Oncol. 2024;42:1499-1508.
    PubMed     Abstract available
    
    
    April 2024
37. TOBIASSON M, Pandzic T, Illman J, Nilsson L, et al
    Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
    J Clin Oncol. 2024;42:1378-1390.
    PubMed     Abstract available
    
    
    
38. RUSSELL NH, Wilhelm-Benartzi C, Othman J, Dillon R, et al
    Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
    J Clin Oncol. 2024;42:1158-1168.
    PubMed     Abstract available
    
    
    March 2024
39. BERMAN E, Shah NP, Deninger M, Altman JK, et al
    CML and the WHO: Why?
    J Clin Oncol. 2024;42:984-986.
    PubMed    
    
    
    
40. FEDELE PL, Opat S
    Chronic Lymphocytic Leukemia-Time to Care for the Survivors.
    J Clin Oncol. 2024 Mar 15:JCO2302738. doi: 10.1200/JCO.23.02738.
    PubMed    
    
    
    
41. LEVIS MJ, Hamadani M, Logan B, Jones RJ, et al
    Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of FLT3.
    J Clin Oncol. 2024 Mar 12:JCO2302474. doi: 10.1200/JCO.23.02474.
    PubMed     Abstract available
    
    
    
42. MAHON FX, Pfirrmann M, Dulucq S, Hochhaus A, et al
    European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
    J Clin Oncol. 2024 Mar 12:JCO2301647. doi: 10.1200/JCO.23.01647.
    PubMed     Abstract available
    
    
    
43. FOA R, Bassan R, Elia L, Piciocchi A, et al
    Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL.
    J Clin Oncol. 2024;42:881-885.
    PubMed     Abstract available
    
    
    
44. CONTER V, Valsecchi MG, Cario G, Zimmermann M, et al
    Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study.
    J Clin Oncol. 2024;42:915-926.
    PubMed     Abstract available
    
    
    
45. HODDER A, Mishra AK, Enshaei A, Baird S, et al
    Blinatumomab for First-Line Treatment of Children and Young Persons With B-ALL.
    J Clin Oncol. 2024;42:907-914.
    PubMed     Abstract available
    
    
    January 2024
46. LOGAN A
    Innovating Simpler and Less Toxic Frontline Management for Adults With ALL.
    J Clin Oncol. 2024;42:250-252.
    PubMed    
    
    
    
47. STELLJES M, Raffel S, Alakel N, Wasch R, et al
    Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.
    J Clin Oncol. 2024;42:273-282.
    PubMed     Abstract available
    
    
    
48. STINCHCOMBE TE, Wang X, Damman B, Mentlick J, et al
    Secondary Analysis of the Rate of Second Primary Lung Cancer From Cancer and Leukemia Group B 140503 (Alliance) Trial of Lobar Versus Sublobar Resection for T1aN0 Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2024 Jan 12:JCO2301306. doi: 10.1200/JCO.23.01306.
    PubMed     Abstract available
    
    
    December 2023
49. PIETERS R, Mullighan CG, Hunger SP
    Advancing Diagnostics and Therapy to Reach Universal Cure in Childhood ALL.
    J Clin Oncol. 2023;41:5579-5591.
    PubMed     Abstract available
    
    
    
50. LEE SHR, Ashcraft E, Yang W, Roberts KG, et al
    Prognostic and Pharmacotypic Heterogeneity of Hyperdiploidy in Childhood ALL.
    J Clin Oncol. 2023;41:5422-5432.
    PubMed     Abstract available
    
    
    
51. RASHIDI A, Ebadi M, Rehman TU, Elhusseini H, et al
    Randomized Double-Blind Phase II Trial of Fecal Microbiota Transplantation Versus Placebo in Allogeneic Hematopoietic Cell Transplantation and AML.
    J Clin Oncol. 2023;41:5306-5319.
    PubMed     Abstract available
    
    
    November 2023
52. BRIVIO E, Pennesi E, Willemse ME, Huitema ADR, et al
    Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.
    J Clin Oncol. 2023 Nov 30:JCO2300897. doi: 10.1200/JCO.23.00897.
    PubMed     Abstract available
    
    
    
53. RAETZ EA, Rebora P, Conter V, Schrappe M, et al
    Outcome for Children and Young Adults With T-Cell ALL and Induction Failure in Contemporary Trials.
    J Clin Oncol. 2023;41:5025-5034.
    PubMed     Abstract available
    
    
    
54. DAVER NG, Vyas P, Kambhampati S, Al Malki MM, et al
    Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results.
    J Clin Oncol. 2023;41:4893-4904.
    PubMed     Abstract available
    
    
    
55. LI J, Gao J, Liu A, Liu W, et al
    Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015 Protocol Study.
    J Clin Oncol. 2023;41:4881-4892.
    PubMed     Abstract available
    
    
    October 2023
56. DEWOLF S, Tallman MS, Rowe JM, Salman MY, et al
    What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?
    J Clin Oncol. 2023;41:4693-4703.
    PubMed     Abstract available
    
    
    
57. LING Y, Xuan L, Xu N, Huang F, et al
    Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial.
    J Clin Oncol. 2023;41:4632-4642.
    PubMed     Abstract available
    
    
    September 2023
58. MCCAW ZR, Richardson PG, Wei LJ
    Assessing the Ability of Long Noncoding RNA Expression to Predict Patient Outcomes in Pediatric AML.
    J Clin Oncol. 2023;41:4446-4447.
    PubMed    
    
    
    
59. 
    Erratum: Clinical Implications of Minimal Residual Disease Detection in Infants With KMT2A-Rearranged Acute Lymphoblastic Leukemia Treated on the Interfant-06 Protocol.
    J Clin Oncol. 2023 Sep 12:JCO2301844. doi: 10.1200/JCO.23.01844.
    PubMed    
    
    
    
60. PRATZ KW, Cherry M, Altman JK, Cooper BW, et al
    Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML.
    J Clin Oncol. 2023;41:4236-4246.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Leukemia is free of charge.